Unexpected results of non-invasive prenatal testing: are they all so unexpected?
According to a recent article by Bianchi and colleagues 1 , if the results of a non-invasive prenatal test (NIPT) for multiple fetal aneuploidies is positive but follow-up of the fetus is negative, the positive result may be suggestive of maternal cancer. However, there is an alternative biological explanation for a false-positive NIPT, that of fetoplacental discrepancies.
In the majority of cases, the outer cytotrophoblastic layer of the placenta, the source of cell-free DNA (cfDNA) that is targeted by NIPT, reflects the genetic constitution of the fetus 2 . However, in ∼1% of cases, the chromosomal complement of this layer does not match; the cytotrophoblast can be 'abnormal' (usually trisomic) in the presence of a normal fetus. This type of fetoplacental discrepancy can cause false-positive (trisomic) NIPT results 3, 4 .
A discordant result for autosomal monosomy is more likely to be associated with a maternal cancer as only one monosomy is compatible with viability, monosomy X (Turner's syndrome) 4 . Nevertheless, even complex 'compound/multiple trisomies' identified by NIPT can originate in the cytotrophoblast as a result of different trisomies in different villous fronds. Our knowledge of the genetic constitution of cytotrophoblasts is limited and derived mainly from direct cytogenetic examination of a single villous frond following invasive prenatal diagnosis and is therefore not necessarily representative of the whole placenta.
Based on our diagnostic experience of chorionic villi, two questions arise. First, what proportion of multiple trisomies identified by NIPT can be explained by fetoplacental discrepancies? We found 10 cases of confined placental mosaicism involving cytotrophoblasts (cCPM) with multiple aneuploidies (MA) among 1001 cases of mosaicism (Table1) 4 . If 1% of all chorionic villi exhibit cCPM, and 1% of these have MA, then ∼0.01% (0.01 × 0.01 = 0.0001 = ∼ 1:10 000) of all complex NIPT results originate from cCPM-MA and can be potentially interpreted as suspicious for malignancy. Based on these preliminary data, of the 39 cases with MA (3:10 000) in the study of Bianchi et al. 1 , one-third (1:10 000) would be placental in origin and one-third related to maternal malignancy (based on the 20-44%-average ∼33%-risk of maternal cancer associated with MA) 1 . The remaining one-third are false-positive MA cases that might be related to other events, mainly cotwin demise 5 .
Second, if CPM is identified, should the risk of malignancy be dismissed? Cancer during pregnancy occurs in 1:1000 cases 1 and the incidence of cCPM is 1:100 cases 4 . The probability of a maternal malignancy and cCPM occurring as coincidental events is ∼1:100 000 (1:1000 × 1:100). Therefore, even when cCPM is detected as a possible explanation for a NIPT result of MA, the chance of maternal cancer is still not zero.
Molecular cytogenetics and liquid biopsy techniques can be applied to investigate the underlying cause of a multiple trisomic cfDNA result, using single-nucleotide polymorphisms (SNPs) to determine further cancer work-up. A sufficient number of informative SNP combinations comparing maternal DNA and cfDNA can identify the paternal component present in placenta-derived trisomies but not in those derived from maternal malignancy ( Figure S1 ).
Presently, no NIPT assay available is validated for risk assessment of maternal cancer. An incidental finding of multiple trisomies should be followed-up with a validated trisomy SNP profiling assay to determine the underlying mechanism. If the pattern suggests a mitotic non-dysjunction event in a maternal somatic cell rather than a meiotic or mitotic error in the conceptus, further cancer work-up should be considered. 
